NK - NantKwest: Taking A Deeper Dive Into Their COVID-19 Vaccine Efforts As Deaths Spike And New Variants Evolve

• NantKwest and ImmunityBio announced they are preparing to merge to create a juggernaut immunotherapy and cell therapy company. Now, NantKwest investors will have ownership of ImmunityBio's impressive pipeline.
• As the COVID-19 pandemic accelerates and new variants emerge, health agencies are going to need more options to vaccinate and treat the world's population.
• The company's hAd5-COVID-19 vaccine could be a best-in-class vaccine that offers long-term immunity and amazing attributes that would be advantageous to a mass vaccination campaign.
• I believe the company's COVID-19 product candidates will continue to draw attention to the ticker and generate some hype about the company's long-term prospects and upside potential from their oncology programs.

For further details see: